Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

H. Lundbeck A/S Denmark

[phone]

[phone]

Palle Holm Olesen

Vice President, Investor Relations

[e-mail]

[phone]

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

CONTACT: 
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
[phone]
[e-mail] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/lundbeck-s-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-designation-in-japan,c4116334

The following files are available for download:

https://mb.cision.com/Main/18215/4116334/3308944.pdf

Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

View original content:https://www.prnewswire.co.uk/news-releases/lundbecks-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-designation-in-japan-302396851.html

@ prnewswire.co.uk